Barrington Research Increases Merit Medical Systems (NASDAQ:MMSI) Price Target to $115.00

Merit Medical Systems (NASDAQ:MMSI) had its price target boosted by equities research analysts at Barrington Research from $114.00 to $115.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s target price indicates a potential upside of 4.27% from the company’s previous close. Barrington Research also issued estimates for Merit Medical Systems’ Q3 2025 earnings at $0.96 EPS, Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $3.82 EPS and FY2026 earnings at $4.30 EPS.

Other equities research analysts also recently issued research reports about the company. Robert W. Baird upped their target price on Merit Medical Systems from $107.00 to $109.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Wells Fargo & Company upgraded Merit Medical Systems from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $103.00 to $120.00 in a report on Wednesday, December 11th. Piper Sandler lifted their price objective on shares of Merit Medical Systems from $110.00 to $114.00 and gave the company an “overweight” rating in a research note on Tuesday, January 21st. Canaccord Genuity Group boosted their target price on shares of Merit Medical Systems from $125.00 to $127.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, StockNews.com lowered shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $109.80.

Merit Medical Systems Price Performance

MMSI opened at $110.29 on Wednesday. Merit Medical Systems has a 52-week low of $70.70 and a 52-week high of $111.27. The company has a 50 day moving average of $101.36 and a two-hundred day moving average of $97.04. The company has a market cap of $6.43 billion, a P/E ratio of 54.06, a P/E/G ratio of 2.34 and a beta of 0.85. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The firm had revenue of $339.85 million during the quarter, compared to analysts’ expectations of $334.60 million. During the same period in the prior year, the company earned $0.75 EPS. The firm’s revenue was up 7.8% on a year-over-year basis. On average, analysts expect that Merit Medical Systems will post 3.36 earnings per share for the current year.

Insider Transactions at Merit Medical Systems

In related news, CFO Raul Jr. Parra sold 29,646 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the sale, the chief financial officer now directly owns 16,361 shares of the company’s stock, valued at approximately $1,603,705.22. This represents a 64.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the completion of the transaction, the director now directly owns 32,391 shares of the company’s stock, valued at approximately $3,289,306.05. This represents a 27.85 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

Institutional Trading of Merit Medical Systems

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its position in shares of Merit Medical Systems by 70.1% during the 3rd quarter. FMR LLC now owns 1,577,246 shares of the medical instruments supplier’s stock valued at $155,879,000 after buying an additional 649,799 shares during the last quarter. Two Sigma Advisers LP boosted its stake in Merit Medical Systems by 218.9% in the third quarter. Two Sigma Advisers LP now owns 445,500 shares of the medical instruments supplier’s stock valued at $44,029,000 after acquiring an additional 305,800 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Merit Medical Systems by 85.6% during the third quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier’s stock valued at $56,921,000 after purchasing an additional 265,648 shares during the last quarter. Iron Triangle Partners LP acquired a new stake in shares of Merit Medical Systems during the 3rd quarter worth approximately $25,004,000. Finally, International Assets Investment Management LLC bought a new stake in shares of Merit Medical Systems in the 3rd quarter worth approximately $21,156,000. 99.66% of the stock is owned by institutional investors and hedge funds.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.